ConductScience.org, home

Comparison · NCT02388165-sae

Staphylococcus Aureus 4-antigen (SA4Ag) vs Placebo: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Staphylococcus Aureus 4-antigen (SA4Ag) vs Placebo: serious adverse events. Trial comparisons, record NCT02388165-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02388165-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.2360.2160.257wilson
Risk in group 20.2480.2280.269wilson
Risk difference, group 1 minus group 2-0.0121-0.04080.0166newcombe hybrid score
Risk ratio, group 1 over group 20.9510.8451.07log
Odds ratio, group 1 over group 20.9360.81.09log
Number needed to treat, for one fewer participant with a serious adverse event on Staphylococcus Aureus 4-antigen (SA4Ag) than on Placebo82.3from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Staphylococcus Aureus 4-antigen (SA4Ag)
Participants randomized to SA4Ag received a single dose of 0.5 mL SA4Ag vaccine intramuscularly, 10 to 60 days prior to their scheduled surgery. Participants were followed from vaccination up to 6 months after their spinal surgical procedure.
4031,708EG000
Group 2Placebo
Participants randomized to this arm received placebo containing the vaccine excipients reconstituted in 0.5mL water for injection. It was administered via intramuscular injection, 10 to 60 days prior to scheduled surgery. Participants were followed from vaccination up to 6 months after their spinal surgical procedure.
4241,709EG001

Harm

What it counts
Total, serious adverse events
Time frame
SAE and non-SAE: From vaccination up to Day 180 (190-240 days after vaccination). Local and systemic reactions: within 10 days after vaccination (systematic assessment).

Source ClinicalTrials.gov

Trial

Title
Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation
NCT number
NCT02388165
Phases
PHASE2
Conditions
Staphylococcal Vaccine
Interventions
Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine, Placebo
Lead sponsor
Pfizer
Results first posted
2020-09-02

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02388165-sae